The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | HRQoL in patients with transplant-eligible newly diagnosed myeloma treated with Isa-RVd vs Rvd alone
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, discusses the results of an analysis of Part 1 of the Phase III GMMG-HD7 study (NCT03617731), which compared isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) induction versus RVd induction in transplant-eligible patients with newly diagnosed multiple myeloma (MM). This analysis compared the health-related quality of life (HRQoL) of patients in both arms and found that the addition of isatuximab to RVd did not negatively affect HRQoL and led to significant improvement in fatigue and
a favorable trend in pain reduction. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
